Press release: dupixent late-breaking positive pivotal data in bullous pemphigoid presented at aad

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at aad five times more adults on dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo data support the potential of dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the us and the eu paris and tarrytown, ny, march 8, 2025. positive results from the pivotal adept phase 2/3 study evaluating the investigational use of dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (bp) were shared in a late-breaking oral presentation at the 2025 american academy of dermatology (aad) annual meeting.
REGN Ratings Summary
REGN Quant Ranking